FY2024 Earnings Estimate for uniQure Issued By William Blair

uniQure (NASDAQ:QURE) – Stock analysts at William Blair raised their FY2024 earnings per share estimates for uniQure in a research note issued on Wednesday, November 6th. William Blair analyst S. Corwin now anticipates that the biotechnology company will post earnings per share of ($4.14) for the year, up from their previous estimate of ($4.48). The consensus estimate for uniQure’s current full-year earnings is ($4.10) per share. William Blair also issued estimates for uniQure’s Q4 2024 earnings at ($0.73) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($2.82) EPS.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million.

Several other analysts have also issued reports on the stock. The Goldman Sachs Group decreased their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price objective on shares of uniQure in a research report on Wednesday. Royal Bank of Canada lowered their price objective on uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday. Raymond James reaffirmed an “outperform” rating and issued a $20.00 target price on shares of uniQure in a research report on Thursday, October 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, uniQure has a consensus rating of “Hold” and a consensus target price of $17.00.

uniQure Trading Up 4.8 %

Shares of QURE stock opened at $7.79 on Friday. The firm has a market capitalization of $379.68 million, a P/E ratio of -1.57 and a beta of 0.90. uniQure has a 1 year low of $3.73 and a 1 year high of $11.35. The firm’s fifty day simple moving average is $5.77 and its 200 day simple moving average is $5.82. The company has a current ratio of 6.51, a quick ratio of 7.36 and a debt-to-equity ratio of 0.92.

Institutional Trading of uniQure

A number of large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of uniQure by 74.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock valued at $818,000 after purchasing an additional 66,958 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of uniQure by 4.3% during the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after buying an additional 30,054 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after acquiring an additional 350,291 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in shares of uniQure by 103.2% in the 1st quarter. Covestor Ltd now owns 53,690 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 27,267 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.